BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghatalia P, Morgan CJ, Sonpavde G. Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. Crit Rev Oncol Hematol. 2016;98:122-136. [PMID: 26597016 DOI: 10.1016/j.critrevonc.2015.10.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Wang P, Peng X, Zhang J, Wang Z, Meng J, Cen B, Ji A, He S. LncRNA-135528 inhibits tumor progression by up-regulating CXCL10 through the JAK/STAT pathway. Apoptosis 2018;23:651-66. [PMID: 30232656 DOI: 10.1007/s10495-018-1482-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
2 Pasvolsky O, Berger T, Bernstine H, Hayman L, Raanani P, Vidal L. Spontaneous Regression of Hodgkin Lymphoma: Case Report and Review of the Literature. Acta Haematol 2019;141:14-8. [PMID: 30439716 DOI: 10.1159/000494422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Amoroso V, Agazzi GM, Roca E, Fazio N, Mosca A, Ravanelli M, Spada F, Maroldi R, Berruti A. Regression of advanced neuroendocrine tumors among patients receiving placebo. Endocr Relat Cancer. 2017;24:L13-L16. [PMID: 27965278 DOI: 10.1530/erc-16-0475] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
4 Moreau Bachelard C, Coquan E, du Rusquec P, Paoletti X, Le Tourneau C. Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis. EClinicalMedicine 2021;40:101130. [PMID: 34746718 DOI: 10.1016/j.eclinm.2021.101130] [Reference Citation Analysis]
5 Doussau A, Agarwal I, Fojo T, Tannock IF, Grady C. Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trials. Clin Trials 2021;18:690-8. [PMID: 34693757 DOI: 10.1177/17407745211052474] [Reference Citation Analysis]
6 Komohara Y, Harada M. Potential mechanisms of spontaneous regression in patients with B-cell lymphoma; the significance of co-stimulatory molecules in lymphoma cells. J Clin Exp Hematop 2019;59:207-10. [PMID: 31708516 DOI: 10.3960/jslrt.19026] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Okamoto T, Yoshimoto T, Ohike N, Fujikawa A, Kanie T, Fukuda K. Spontaneous regression of gastric gastrinoma after resection of metastases to the lesser omentum: A case report and review of literature. World J Gastroenterol 2021; 27(1): 129-142 [PMID: 33505155 DOI: 10.3748/wjg.v27.i1.129] [Reference Citation Analysis]
8 Zibelman M, Ghatalia P, Geynisman DM, Plimack ER. Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. Immunotherapy 2016;8:785-98. [PMID: 27349978 DOI: 10.2217/imt-2016-0028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
9 Capdevila J, Hernando J, Perez-Hoyos S, Roman-Gonzalez A, Grande E. Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors. Oncologist 2019;24:e1315-20. [PMID: 31332100 DOI: 10.1634/theoncologist.2018-0675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Stanoszek LM, Smith LB, Grajewski K, Reneau JC, Wilcox R, Perry AM. Spontaneous Regression of High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements: Case Report and Literature Review. Clin Lymphoma Myeloma Leuk 2021;21:e120-5. [PMID: 33060050 DOI: 10.1016/j.clml.2020.09.006] [Reference Citation Analysis]
11 Khan H, Casey P, Hayes S, Tokala A, Sultan J. Spontaneous regression of oesophageal squamous cell carcinoma. BMJ Case Rep 2021;14:e241344. [PMID: 34099447 DOI: 10.1136/bcr-2020-241344] [Reference Citation Analysis]
12 Frankel AE, Deshmukh S, Reddy A, Lightcap J, Hayes M, McClellan S, Singh S, Rabideau B, Glover TG, Roberts B, Koh AY. Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota. Integr Cancer Ther 2019;18:1534735419846379. [PMID: 31014119 DOI: 10.1177/1534735419846379] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
13 Michaeli DT, Michaeli T. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021. J Clin Oncol 2022;:JCO2200535. [PMID: 35921606 DOI: 10.1200/JCO.22.00535] [Reference Citation Analysis]